EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 949-956 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 949 - 956
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
DOI https://doi.org/10.1051/medsci/2019191
Publié en ligne 6 janvier 2020
  1. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13: 473–486. [Google Scholar]
  2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 ; 12: 252–264. [Google Scholar]
  3. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018 29 (suppl 4): iv264–i6. [CrossRef] [PubMed] [Google Scholar]
  4. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016 ; 60: 12–25. [CrossRef] [PubMed] [Google Scholar]
  5. Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017 ; 19: 3. [CrossRef] [PubMed] [Google Scholar]
  6. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017 ; 13: 195–207. [CrossRef] [PubMed] [Google Scholar]
  7. Sibaud V, Boulinguez S, Pagès C, et al. Dermatologic toxicities of immune checkpoint inhibitors. Ann Dermatol Venereol 2018 ; 145: 313–330. [CrossRef] [PubMed] [Google Scholar]
  8. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: A new type of inflammatory bowel disease?. ACG Case Rep J 2017 ; 4: e112. [Google Scholar]
  9. Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017 ; 28: 2860–2865. [CrossRef] [PubMed] [Google Scholar]
  10. Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: Anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis 2017 ; 11: 1238–1246. [CrossRef] [PubMed] [Google Scholar]
  11. Gentile NM, D’Souza A, Fujii LL, et al. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013 ; 88: 414–417. [CrossRef] [PubMed] [Google Scholar]
  12. De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018 ; 68: 1181–1190. [CrossRef] [PubMed] [Google Scholar]
  13. Su Q, Zhang X-C, Zhang C-G, et al. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: Systematic assessment with meta-analysis. J Immunol Res 2018 ; 2018: 1027323. [PubMed] [Google Scholar]
  14. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018 ; 378: 158–168. [Google Scholar]
  15. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018 ; 67: 1471–1480. [CrossRef] [PubMed] [Google Scholar]
  16. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017 ; 35: 709–717. [CrossRef] [PubMed] [Google Scholar]
  17. Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 2017 ; 23: 620–624. [CrossRef] [PubMed] [Google Scholar]
  18. Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017 ; 2: 709–718. [Google Scholar]
  19. Moslehi JJ, Salem J-E, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018 ; 391: 933. [Google Scholar]
  20. Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017 ; 41: 100–110. [CrossRef] [PubMed] [Google Scholar]
  21. Bitton K, Michot J-M, Barreau E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol 2019 ; 202: 109–117. [CrossRef] [PubMed] [Google Scholar]
  22. Delanoy N, Michot J-M, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019 ; 6: e48–e57. [CrossRef] [PubMed] [Google Scholar]
  23. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28: 368–376. [CrossRef] [PubMed] [Google Scholar]
  24. Johnson DB, Khushalani NI, Puzanov I, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J Clin Oncol 2017 ; 33: suppl 9019. [Google Scholar]
  25. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016 ; 375: 143–153. [Google Scholar]
  26. Lipson EJ, Bagnasco SM, Moore J, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016 ; 374: 896–898. [Google Scholar]
  27. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 ; 179: 5204–5210. [CrossRef] [PubMed] [Google Scholar]
  28. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019 ; 7: 106. [Google Scholar]
  29. Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol 2019 ; 5: 1049–1054. [CrossRef] [PubMed] [Google Scholar]
  30. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016 ; 27: 559–574. [CrossRef] [PubMed] [Google Scholar]
  31. Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 2017; 109. doi: 10.1093/jnci/djw260. [Google Scholar]
  32. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 2017 ; 5: 95. [Google Scholar]
  33. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018 ; 36: 1714–1768. [CrossRef] [PubMed] [Google Scholar]
  34. Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine society guidance on endocrine side-effects of immunotherapy. Endocr Relat Cancer 2018 Oct 1; pii: ERC-18-0320.R1. [Google Scholar]
  35. Gauci M-L, Baroudjian B, Zeboulon C, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed?. J Hepatol 2018 ; 69: 548–550. [CrossRef] [PubMed] [Google Scholar]
  36. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2017 ; 77: 393–398. [CrossRef] [PubMed] [Google Scholar]
  37. Roberts J, Smylie M, Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 2019 ; 38: 1513–1519. [Google Scholar]
  38. Ford M, Sahbudin I, Filer A, et al. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology 2018 ; 57: 2244–2246. [CrossRef] [PubMed] [Google Scholar]
  39. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016 ; 2: 1346–1353. [CrossRef] [PubMed] [Google Scholar]
  40. Beardslee T, Draper A, Kudchadkar R. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. J Oncol Pharm Pract 2019 ; 25: 1275–1281. [CrossRef] [PubMed] [Google Scholar]
  41. Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019 ; 25: 551–557. [CrossRef] [PubMed] [Google Scholar]
  42. Khan U, Ali F, Khurram MS, et al. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 2017 ; 5: 15. [Google Scholar]
  43. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014 ; 15: 69–77. [CrossRef] [PubMed] [Google Scholar]
  44. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017 ; 66: 581–592. [CrossRef] [PubMed] [Google Scholar]
  45. Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017 ; 376: 1989–1991. [Google Scholar]
  46. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017 ; 35: 3807–3814. [CrossRef] [PubMed] [Google Scholar]
  47. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009 ; 15: 5591–5598. [CrossRef] [PubMed] [Google Scholar]
  48. Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. Arthritis Rheum 2019: 10.1002/art.41068. [Google Scholar]
  49. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018 ; 36: 2872–2878. [CrossRef] [PubMed] [Google Scholar]
  50. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018 ; 4: 374–378. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.